CN104066441A - 2型糖尿病的治疗方案 - Google Patents

2型糖尿病的治疗方案 Download PDF

Info

Publication number
CN104066441A
CN104066441A CN201280065132.1A CN201280065132A CN104066441A CN 104066441 A CN104066441 A CN 104066441A CN 201280065132 A CN201280065132 A CN 201280065132A CN 104066441 A CN104066441 A CN 104066441A
Authority
CN
China
Prior art keywords
treatment
patients
pharmaceutical combination
combination according
lixisenatide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280065132.1A
Other languages
English (en)
Chinese (zh)
Inventor
L.西尔维斯特里
E.索哈米
X.魏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to CN201711071123.4A priority Critical patent/CN107693783A/zh
Publication of CN104066441A publication Critical patent/CN104066441A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201280065132.1A 2011-10-28 2012-10-26 2型糖尿病的治疗方案 Pending CN104066441A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711071123.4A CN107693783A (zh) 2011-10-28 2012-10-26 2型糖尿病的治疗方案

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187169.5 2011-10-28
EP11187169 2011-10-28
PCT/EP2012/071271 WO2013060850A1 (en) 2011-10-28 2012-10-26 Treatment protocol of diabetes type 2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711071123.4A Division CN107693783A (zh) 2011-10-28 2012-10-26 2型糖尿病的治疗方案

Publications (1)

Publication Number Publication Date
CN104066441A true CN104066441A (zh) 2014-09-24

Family

ID=47071308

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280065132.1A Pending CN104066441A (zh) 2011-10-28 2012-10-26 2型糖尿病的治疗方案
CN201711071123.4A Pending CN107693783A (zh) 2011-10-28 2012-10-26 2型糖尿病的治疗方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711071123.4A Pending CN107693783A (zh) 2011-10-28 2012-10-26 2型糖尿病的治疗方案

Country Status (15)

Country Link
US (1) US20130296236A1 (enExample)
EP (1) EP2771024B1 (enExample)
JP (1) JP6329487B2 (enExample)
KR (1) KR101967941B1 (enExample)
CN (2) CN104066441A (enExample)
AU (1) AU2012328388B2 (enExample)
BR (1) BR112014010200A2 (enExample)
CA (1) CA2851690C (enExample)
IL (1) IL232251B (enExample)
IN (1) IN2014CN02616A (enExample)
MX (1) MX359329B (enExample)
MY (1) MY170713A (enExample)
RU (1) RU2014121386A (enExample)
SG (1) SG11201401175SA (enExample)
WO (1) WO2013060850A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206058A (zh) * 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
CN107405386A (zh) * 2015-01-16 2017-11-28 赛诺菲-安万特德国有限公司 使用利西拉来治疗儿科2型糖尿病患者
CN107921099A (zh) * 2015-03-13 2018-04-17 赛诺菲-安万特德国有限公司 治疗2型糖尿病患者

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE068164T2 (hu) 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2014209630A2 (en) * 2013-06-27 2014-12-31 Inspark Technologies, Inc. Systems, devices, and/or methods for identifying time periods of insufficient blood glucose testing
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TW201705975A (zh) * 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TW202529797A (zh) * 2023-12-12 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2329848A1 (en) * 2009-11-13 2011-06-08 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes
CN103717232A (zh) * 2011-05-13 2014-04-09 赛诺菲-安万特德国有限公司 2型糖尿病中作为基础胰岛素的附加疗法的利西拉来

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
MXPA06002127A (es) * 2003-09-02 2006-05-31 Prosidion Ltd Terapia combinada para control glucemico.
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
CA2750049C (en) * 2009-02-04 2021-02-23 Sanofi-Aventis Deutschland Gmbh Medical device and method for providing information for glycemic control
JP5980466B2 (ja) * 2009-11-13 2016-08-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法
KR20110052990A (ko) * 2009-11-13 2011-05-19 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2329848A1 (en) * 2009-11-13 2011-06-08 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes
CN103717232A (zh) * 2011-05-13 2014-04-09 赛诺菲-安万特德国有限公司 2型糖尿病中作为基础胰岛素的附加疗法的利西拉来

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARNOLDS SABINE ET AL.: "Insulin glargine(GLAR) plus Metformin(MET): An Efficacious and Safe regimen that can be combined with exenatide (EXE) or Sitagliptin (SITA)", 《DIABETES》, vol. 58, no. 1, 1 June 2009 (2009-06-01), pages 141 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206058A (zh) * 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
CN107405386A (zh) * 2015-01-16 2017-11-28 赛诺菲-安万特德国有限公司 使用利西拉来治疗儿科2型糖尿病患者
CN107921099A (zh) * 2015-03-13 2018-04-17 赛诺菲-安万特德国有限公司 治疗2型糖尿病患者

Also Published As

Publication number Publication date
AU2012328388A1 (en) 2014-05-15
IL232251B (en) 2019-10-31
CA2851690C (en) 2022-07-26
BR112014010200A2 (pt) 2020-10-27
MX2014005139A (es) 2014-08-27
MY170713A (en) 2019-08-27
EP2771024B1 (en) 2018-11-28
WO2013060850A1 (en) 2013-05-02
IL232251A0 (en) 2014-06-30
HK1198577A1 (en) 2015-04-30
SG11201401175SA (en) 2014-09-26
KR101967941B1 (ko) 2019-04-10
CN107693783A (zh) 2018-02-16
IN2014CN02616A (enExample) 2015-06-26
EP2771024A1 (en) 2014-09-03
MX359329B (es) 2018-09-25
JP2015501314A (ja) 2015-01-15
RU2014121386A (ru) 2015-12-10
CA2851690A1 (en) 2013-05-02
KR20140093935A (ko) 2014-07-29
AU2012328388B2 (en) 2017-06-15
JP6329487B2 (ja) 2018-05-23
US20130296236A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
CN104066441A (zh) 2型糖尿病的治疗方案
US20220054594A1 (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP6410600B2 (ja) ２型糖尿病患者における低血糖症の予防
DK2750699T3 (en) A pharmaceutical combination for use in glycemic control in diabetes type 2 patients
JP6410604B2 (ja) ２型糖尿病における基礎インスリンに対する上乗せ療法としてのリキシセナチド
CN105473155B (zh) 甘精胰岛素/利西拉来固定比率配制剂
CN103648520A (zh) 用于诱导ii型糖尿病患者体重减轻或者/和用于防止ii型糖尿病患者体重增加的药物组合产品
TWI748945B (zh) 第２型糖尿病病患治療
HK1198577B (en) Treatment protocol of diabetes type 2
TW201322994A (zh) 第二型糖尿病的治療方案

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140924